Newsbenzinga
Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential
· Published
Article summary
Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.
An excerpt from the original article.
Comments —
Loading comments…